Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.
aminoglycosides
capreomycin
meta-analysis
multidrug-resistant tuberculosis
treatment
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
03
02
2020
accepted:
22
05
2020
pubmed:
31
10
2020
medline:
15
3
2022
entrez:
30
10
2020
Statut:
ppublish
Résumé
As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the role of currently used drugs must be reevaluated. We combined individual-level data on patients with pulmonary MDR-TB published during 2009-2016 from 25 countries. We compared patients receiving each of the injectable drugs and those receiving no injectable drugs. Analyses were based on patients whose isolates were susceptible to the drug they received. Using random-effects logistic regression with propensity score matching, we estimated the effect of each agent in terms of standardized treatment outcomes. More patients received kanamycin (n = 4330) and capreomycin (n = 2401) than amikacin (n = 2275) or streptomycin (n = 1554), opposite to their apparent effectiveness. Compared with kanamycin, amikacin was associated with 6 more cures per 100 patients (95% confidence interval [CI], 4-8), while streptomycin was associated with 7 (95% CI, 5-8) more cures and 5 (95% CI, 4-7) fewer deaths per 100 patients. Compared with capreomycin, amikacin was associated with 9 (95% CI, 6-11) more cures and 5 (95% CI, 2-8) fewer deaths per 100 patients, while streptomycin was associated with 10 (95% CI, 8-13) more cures and 10 (95% CI, 7-12) fewer deaths per 100 patients treated. In contrast to amikacin and streptomycin, patients treated with kanamycin or capreomycin did not fare better than patients treated with no injectable drugs. When aminoglycosides are used to treat MDR-TB and drug susceptibility test results support their use, streptomycin and amikacin, not kanamycin or capreomycin, are the drugs of choice.
Sections du résumé
BACKGROUND
As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the role of currently used drugs must be reevaluated.
METHODS
We combined individual-level data on patients with pulmonary MDR-TB published during 2009-2016 from 25 countries. We compared patients receiving each of the injectable drugs and those receiving no injectable drugs. Analyses were based on patients whose isolates were susceptible to the drug they received. Using random-effects logistic regression with propensity score matching, we estimated the effect of each agent in terms of standardized treatment outcomes.
RESULTS
More patients received kanamycin (n = 4330) and capreomycin (n = 2401) than amikacin (n = 2275) or streptomycin (n = 1554), opposite to their apparent effectiveness. Compared with kanamycin, amikacin was associated with 6 more cures per 100 patients (95% confidence interval [CI], 4-8), while streptomycin was associated with 7 (95% CI, 5-8) more cures and 5 (95% CI, 4-7) fewer deaths per 100 patients. Compared with capreomycin, amikacin was associated with 9 (95% CI, 6-11) more cures and 5 (95% CI, 2-8) fewer deaths per 100 patients, while streptomycin was associated with 10 (95% CI, 8-13) more cures and 10 (95% CI, 7-12) fewer deaths per 100 patients treated. In contrast to amikacin and streptomycin, patients treated with kanamycin or capreomycin did not fare better than patients treated with no injectable drugs.
CONCLUSIONS
When aminoglycosides are used to treat MDR-TB and drug susceptibility test results support their use, streptomycin and amikacin, not kanamycin or capreomycin, are the drugs of choice.
Identifiants
pubmed: 33124668
pii: 5943503
doi: 10.1093/cid/ciaa621
pmc: PMC8653626
doi:
Substances chimiques
Aminoglycosides
0
Antitubercular Agents
0
Capreomycin
11003-38-6
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3929-e3936Subventions
Organisme : CIHR
ID : 143350
Pays : Canada
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Références
Ann N Y Acad Sci. 1958 Sep 30;76(2):157-62
pubmed: 13595504
Antimicrob Agents Chemother. 1989 Aug;33(8):1298-301
pubmed: 2478073
Ann N Y Acad Sci. 1958 Sep 30;76(2):163-5
pubmed: 13595505
Br Med J. 1948 Oct 30;2(4582):769-82
pubmed: 18890300
Am J Med. 1947 May;2(5):429-35
pubmed: 20294521
PLoS Med. 2012;9(8):e1001300
pubmed: 22952439
Clin Infect Dis. 2016 Feb 15;62(4):418-430
pubmed: 26508515
Antibiot Chemother. 1970;16:27-31
pubmed: 4108891
Eur Respir J. 2013 Jul;42(1):156-68
pubmed: 23100499
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
Kekkaku. 1976 Jul 15;51(7):271-8
pubmed: 61302
Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79
pubmed: 10529902
Lancet Infect Dis. 2009 Mar;9(3):153-61
pubmed: 19246019
Ann N Y Acad Sci. 1958 Sep 30;76(2):103-8
pubmed: 13595497
Tubercle. 1972 Sep;53(3):153-65
pubmed: 4116993
Ann N Y Acad Sci. 1958 Sep 30;76(2):88-102
pubmed: 13595496
Tubercle. 1964 Sep;45:205-10
pubmed: 14227806
Antibiot Chemother. 1970;16:43-58
pubmed: 4108895
Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823
pubmed: 27748623
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
Tubercle. 1974 Jun;55(2):105-13
pubmed: 4143450
Eur Respir J. 2011 Sep;38(3):516-28
pubmed: 21828024
Am Rev Respir Dis. 1966 Dec;94(6):858-64
pubmed: 4958888